Nyxoah SA Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Nyxoah SA, a Belgian foreign private issuer, on March 26, 2025. The filing reports a material event concerning the Company's Genio® system, a medical device for treating sleep apnea. The reporting period covers the month of March 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory developments rather than financial performance.
Material Changes
The primary material change is the receipt of an "Approvable Letter" from the U.S. Food and Drug Administration (FDA) regarding the Company's Premarket Approval (PMA) application for the Genio® system. This indicates that the application substantially meets the requirements of the Federal Food, Drug, and Cosmetic Act. Approval is now contingent upon the satisfactory completion of a review of manufacturing facilities, methods, and controls.
Outlook, Risks, and Management Commentary
- Regulatory Status: The FDA decision does not impact the Genio® system's existing CE Mark or the Company's ongoing commercial activities in Europe, where the device is marketed for both Complete Concentric Collapse (CCC) and non-CCC patients.
- Next Steps: The Company must complete the manufacturing facilities review to secure final FDA approval for marketing in the United States.
- Incorporation by Reference: The information regarding the FDA letter is incorporated by reference into the Company's registration statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the specific conditions outlined in the FDA Approvable Letter regarding the manufacturing facilities review.
- Monitor the timeline for the completion of the manufacturing review and the expected date of final PMA approval.
- Confirm that European commercial operations remain unaffected by the U.S. regulatory process.
- Review the attached press release (Exhibit 99.1) for any additional details on the path to U.S. market launch.